Study of an oral medication for safety in healthy adults
Part of Blood & lymphatic clinical trials.
This study tests an investigational oral medication called TUL321 in healthy volunteers to see if it is safe and how the body handles it. It may help understand the drug's effects and is an early step in developing a new treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 45 years old.
- You need to weigh at least 50 kg (men) or 45 kg (women) and have a BMI between 19 and 26.
- If you or your partner can have children, you must agree to use effective contraception and not donate sperm or eggs for 3 months after the last dose.
- You must not have a history of serious infections (like tuberculosis, meningitis, or pneumonia) or immune problems.
- You must be willing to receive two vaccines (meningococcal and pneumococcal) at least 14 days before the first dose, if you join the multiple-dose part of the study.
- You must be in good general health with no significant lab, heart, or lung findings.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called MY008211A for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder where red blood cells are destroyed. If you have moderate anemia and high LDH (a marker of blood cell breakdown), this study may be an option.
This early-stage study tests how safe and tolerable ADX-038 is, and how the body processes it, in healthy volunteers and in people with paroxysmal nocturnal hemoglobinuria (PNH). It may help researchers understand whether the drug works safely for PNH patients and identify the right dosing.
This trial tests a new investigational drug called CMS-D017 in healthy volunteers. Researchers will give single and multiple doses to see how the body processes it and if it's safe. You could help find an important new treatment.
This study checks the long-term safety of the drug MY008211A for people with paroxysmal nocturnal hemoglobinuria (PNH). It is only for those who already took the drug in an earlier study and had benefit, and who have had specific vaccines.
This trial tests an experimental RNA drug (ALN-CFB) for people with PNH who still have low red blood cell counts despite taking a C5 inhibitor. The drug aims to block a protein (complement factor B) to improve anemia.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria, PNH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.